Częściowy niedobór hormonu wzrostu (GHD) u dzieci - więcej podobieństw do idiopatycznej niskorosłości niż do ciężkiego GHD by Smyczyńska, Joanna et al.
182
PRACE ORYGINALNE/ORIGINAL PAPERS
Endokrynologia Polska/Polish Journal of Endocrinology
Tom/Volume 58; Numer/Number 3/2007
ISSN 0423–104X
Partial growth hormone deficiency (GHD) in children
has more similarities to idiopathic short stature
than to severe GHD
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Introduction: Assessment of growth hormone (GH) secretion is based on stimulation tests. Low GH peaks in stimulation
tests, together with decreased insulin-like growth factor-I (IGF-I) secretion, confirm a diagnosis of GH deficiency (GHD).
However, limitations in interpreting the test results and discrepancies between GH and IGF-I secretion in particular pa-
tients have both been reported. GH therapy should improve the prognosis of adult height (PAH).
The aim of the study was to compare the deficit of height at diagnosis, IGF-I secretion and PAH in children with either
decreased (in varying degrees of severity) or normal GH secretion in stimulation tests.
Material and methods: The analysis comprised 540 short children (373 boys, 167 girls), aged 11.7 ± 3.2 years. In all the
patients two GH stimulation tests were performed, IGF-I serum concentration was measured, bone age was assessed and
PAH was calculated. According to the GH peak in the two stimulation tests, the patients were classified into the following
groups: severe GHD (sGHD) — GH peak < 5 ng/mL (n = 44), partial GHD (pGHD) — GH peak 5–10 ng/mL (n = 190),
idiopathic short stature (ISS) — GH peak at least 10 ng/mL (n = 306).
Results: A significantly greater deficit of height, lower IGF-I secretion and worse PAH were observed in sGHD than in both
remaining groups, while all the differences between pGHD and ISS in the parameters analysed were insignificant.
Conclusion: The results obtained indicate the necessity of applying another methods of qualifying short children for GH
therapy other than GH stimulation tests with a cut-off value at a level of 10 ng/mL.
(Pol J Endocrinol 2007; 58 (3): 182–187)
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Streszczenie
Wstęp: Podstawową metodą oceny wydzielania hormonu wzrostu (GH) są testy stymulacyjne. Stwierdzenie obniżonego
maksymalnego wydzielania GH (maxGH) w testach stymulacyjnych oraz obniżonego stężenia insulinopodobnego czyn-
nika wzrostowego-I (IGF-I) w surowicy stanowi podstawę rozpoznania niedoboru GH (GHD). Istnieje jednak szereg ogra-
niczeń w interpretacji wyników testów stymulacyjnych, jak również rozbieżności pomiędzy wynikami testów a wydziela-
niem IGF-I u poszczególnych pacjentów. Terapia preparatem GH powinna prowadzić do poprawy prognozy wzrostowej
pacjentów.
Celem pracy było porównanie ciężkości niedoboru wzrostu, stężenia IGF-I i prognozy wzrostowej u pacjentów z prawi-
dłowym i w różnym stopniu obniżonym wydzielaniem GH.
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Materiał i metody: Analizą objęto dane 540 dzieci (373 chłopców, 167 dziewcząt) z niedoborem wzrostu, w wieku 11,7 ±
± 3,2 lat, u których wykonano 2 testy stymulacyjne na wydzielanie GH i oznaczono stężenie IGF-I w surowicy oraz oceniono
wiek kostny i obliczono prognozę wzrostową. W zależności od maksymalnego wydzielania GH w testach stymulacyjnych,
pacjentów podzielono na grupy: ciężki GHD (sGHD) — maxGH < 5 ng/ml (n = 44), częściowy GHD — maxGH 5–10 ng/ml
(n = 190), idiopatyczny niski wzrost (ISS) — maxGH ≥ 10 ng/ml (n = 306).
Wyniki: Stwierdzono znamiennie cięższy niedobór wzrostu, znamiennie niższe wydzielanie IGF-I oraz znamiennie gorszą
prognozę wzrostową u pacjentów z sGHD niż w obu pozostałych grupach przy braku znamiennych różnic w zakresie
wszystkich analizowanych parametrów pomiędzy pacjentami z pGHD i ISS.
Wniosek: Uzyskane wyniki wskazują na celowość stosowania w praktyce klinicznej innych metod diagnostycznych
i kryteriów kwalifikacji dzieci z niedoborem wzrostu do terapii GH niż wartość progowa maxGH w testach stymulacyjnych
na poziomie 10 ng/mL.
(Endokrynol Pol 2007; 58 (3): 182–187)
Słowa kluczowe: niedobór wzrostu, niedobór hormonu wzrostu, testy stymulacyjne, insulinopodobny czynnik wzrostowy-I,
prognoza wzrostowa
Introduction
The most important hormonal causes of short statu-
re in children include growth hormone deficiency
(GHD) and other less frequent disorders of growth
hormone (GH) secretion and action, such as synthe-
sis of an inactive GH molecule, partial GH insensiti-
vity and GH resistance (Laron syndrome). All the
above-mentioned disorders result in decreased syn-
thesis of insulin-like growth factor-I (IGF-I) and its
binding proteins. In rare cases either reduced IGF-I
bioavailability or IGF-I insensitivity (Bierich syndro-
me) may be diagnosed.
It is well known that both linear growth and GH
secretion are variables with a continuous distribution
in the population and an overlap exists between the
results of both auxological and hormonal measurements
in healthy and GH-deficient subjects [1]. Thus the bor-
derline between normal and decreased GH secretion
must be established arbitrarily [1–3]. Routine diagnosis
of GHD is based on the assessment of GH peaks in sti-
mulation tests and of spontaneous GH secretion. For
many years diagnosis of the classic form of GHD has
been formulated where there is decreased (i.e. lower
than an arbitrarily established cut-off level) GH secre-
tion in two stimulation tests with different pharmaco-
logical stimuli. The limitations in interpreting the re-
sults of stimulation tests [2, 4] as well as the poor repro-
ducibility of the test results should be taken into acco-
unt. For instance, in most children, previously diagnosed
as GH-deficient, who have a normal image of the hy-
pothalamic-pituitary region in magnetic resonance the
results of the same stimulation tests repeated a few
months later were normal [5, 6]. Moreover, the reverse
situation, where there is decreased GH secretion in re-
peated stimulation tests in patients in whom it had pre-
viously been normal, has been observed. Another pro-
blem is the possibility of decreased spontaneous GH
secretion, so-called neurosecretory dysfunction, despi-
te a normal GH peak in stimulation tests [7].
The main peripheral mediator of GH action is IGF-I.
Plasma concentration of IGF-I is considered a good
marker of GH secretion; according to current studies it
is no less reliable than the results of GH stimulation
tests [6, 8]. It should be stressed that this is not a com-
pletely new approach to the problem of GHD. Ten years
ago Rosenfeld [9–11] postulated that measurement of
IGF-I plasma concentration should be the first step in
diagnosing children with short stature. However GH
stimulation tests still remain a standard in GHD dia-
gnostics [7, 12].
Assessment of IGF-I secretion also has some limita-
tions. Firstly, other disorders that may lead to decre-
ased IGF-I secretion, such as malabsorption syndrome
and liver diseases, should be excluded. Next, the phy-
siological increase in IGF-I secretion related to both the
patient’s age and pubertal maturation must be taken
into account [13, 14]. Thus the results should be inter-
preted with reference to appropriate normative data for
a given population. Owing to the relative stability of
the IGF-I molecule, it is sufficient to measure only basal
IGF-I plasma concentration without performing more
sophisticated diagnostic procedures. It is of great im-
portance to remember that IGF-I secretion is decreased
not only in patients with the classic form of GHD but
also in children with neurosecretory dysfunction and
in those with decreased GH sensitivity.
In some children with extremely severe height defi-
cit, however, a very high GH secretion is observed in-
stead of the expected decreased GH peak in stimula-
tion tests, suggesting the presence of other disturban-
ces of the growth signalling pathway [15], including
decreased GH sensitivity [16].
The most important goal of GH therapy is an im-
provement in height velocity and, above all, in the final
height of patients. It seems that patients who may
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benefit during GH therapy should have decreased IGF-I
secretion and a relatively poor prognosis for final he-
ight, especially with respect to their target height, de-
termined by parental height.
The aim of the study was to compare the deficit of he-
ight at diagnosis, IGF-I secretion and prognosis of final he-
ight in children with either decreased (in varying degrees
of severity) or normal GH secretion in stimulation tests.
Material and methods
The analysis comprised 540 children (373 boys and 167
girls) with short stature (i.e. body height below the 3rd
centile according to the current centile charts for War-
saw children) [17]. At diagnosis patient age was 11.7 ±
± 3.2 years (mean ± SD), with a range of 3.0–17.5 years;
for boys it was 12.3 ± 3.1 years (range: 3.0–17.5 years)
and for girls 10.3 ± 2.9 years (range: 3.4–15.8 years).
Additional criteria for eligibility for the diagnostics inc-
luded delayed bone age (BA) and a height velocity (HV)
below 4 cm/year, calculated on the basis of at least,
6 months’ observation. In order to compare the deficit
of height among male and female patients at different
ages the value of the height standard deviation score
(H SDS) was calculated for each patient according to
the Tanner-Whitehouse normative data [18].
Patients with chromosomal abnormalities, dysmor-
phic features, skeletal dysplasia, malabsorption syndro-
me, primary hypothyroidism and chronic diseases, as
well as all those with acquired GHD (due to either neo-
plastic processes or brain injury) were excluded from
the study. Thus all the children whose growth had been
disturbed by pathological processes unrelated to the
GH/IGF-I hormonal axis as well as those with a growth
curve change due to an acquired disease, were exclu-
ded from the analysis.
Two different standard stimulation tests were
performed for all the patients, the first with clonidine
(0.15 mg/m2, p.o.) and the second with either insulin
(0.1 IU/kg i.v.) or glucagon (30 mg/kg not exceeding
1 mg, i.m.). Concentrations of GH were measured, using
the two-site chemiluminescent enzyme immunometric
assay hGH IMMULITE, DPC) with a sensitivity of
0.01 ng/mL, with intra-assay coefficients of variation
(CV) of 5.3–6.5% and inter-assay CV of 5.5-6.2%. Cali-
bration of GH standards was performed according to
the WHO reference standard 80/505.
GHD was diagnosed where there was a GH peak
below 10 ng/mL in both tests. Next, all the patients with
GHD were divided into two subgroups:
— those with severe GHD — GH peak in both tests
was below 5 ng/mL (n = 44),
— those with partial GHD — GH peak in at least one
test was between 5 and 10 ng/mL (n = 190).
For the purpose of the study all children with a GH
peak over 10 ng/mL in at least one of the tests were qu-
alified as having idiopathic short stature (ISS) (n = 306).
IGF-I secretion was assessed in a single blood sam-
ple collected at the beginning of first stimulation test
before the application of the stimulating agent. Serum
IGF-I concentration was measured by a solid-phase
enzyme-labelled chemiluminescent immunometric as-
say (IMMULITE, DPC, calibrated to WHO NIBSC 1st IRR
87/518 and with an analytical sensitivity of 20 ng/ml,
a calibration range up to 1600 ng/ml, intra-assay CV
3.1–4.3% and inter-assay CV 5.8–8.4%. For each patient
IGF-I concentration was expressed as SDS for age and
sex (IGF-I SDS).
The heights of all the patients’ parents were measu-
red and expressed as H SDS and the target height (TH)
of the children was calculated and expressed as TH SDS.
In each patient radiography of the non-dominant
hand and wrist was performed and BA was assessed
according to Greulich and Pyle’s standards [19]. Next,
predicted adult height (PAH) was calculated according
to the Bayley-Pinneau method [20] for 518 children and
expressed as PAH SDS; for the remaining 22 patients it
was not possible to calculate PAH by this method be-
cause BA was too young.
The concordance of the distribution of all the analy-
sed variables with normal distribution was evaluated
by means of the Shapiro-Wilk test. As the distribution
of most of the variables was different from normal, the
following non-parametric tests were applied in further
analysis: the Mann-Whitney U test for two indepen-
dent samples, the ANOVA rank Kruskall-Wallis test and
the Newman-Keuls test for more than two independent
samples.
The study protocol was approved by the local Ethics
Committee for the Research Institute of the Hospital of
the Polish Mother, Łódź, Poland.
Results
Patients’ H SDS was significantly lower (p < 0.05) in
the sGHD group than in the remaining groups and was
almost the same in pGHD and ISS. Target height SDS
was similar in all the groups and there was thus no need
to calculate and compare either corrected H SDS (i.e.
the difference between H SDS and TH SDS) or correc-
ted PAH SDS (i.e. the difference between PAH SDS and
TH SDS) in particular groups. PAH was significantly
worse (p < 0.05) in sGHD than in both pGHD and ISS,
and, somewhat surprisingly, significantly worse
(p < 0.05) in ISS than in pGHD. Similarly, IGF-I SDS
was significantly lower (p < 0.001) in sGHD than in both
pGHD and ISS, although the difference between these
latter groups was insignificant.
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Detailed data including H SDS at diagnosis, IGF-I se-
cretion, TH and PAH in particular groups of patients with
normal and subnormal results of GH stimulation tests are
presented in Table I and illustrated on Figures 1–3.
The results obtained indicate a lack of significant
differences in all the parameters analysed between the
patients with pGHD and those with ISS, while in the
patients with sGHD both the most severe deficit of he-
ight and the worst PAH were observed in association
with the lowest IGF-I secretion.
Discussion
According to current standards [7, 12], the diagnosis of
GHD is based on a decreased GH peak in two provoca-
tive tests with different stimuli. In routine practice the
same cut-off value for normal and subnormal GH se-
cretion is approved at an arbitrarily established level
[2] independently of the type of test and the diagnostic
assay used, most frequently set at 10 ng/mL, as in Po-
land, or 7 ng/mL [21, 22]. This problem was discussed
in depth by Rosenfeld et al. in 1995 [2], who stressed
the lack of evidence for any arbitrarily established cut-
off values for normal and subnormal results of GH sti-
mulation tests. The findings of Shalet et al. [1] and Ranke
et al. were similar [23]. Moreover, in studies on healthy
Table I
Height, IGF-I secretion, TH and PAH (expressed as SDS for
age and sex) in particular groups of patients
Tabela I
Wzrost wydzielania IGF-I, TH i PAH  (wyrażone
wartościami SDS w poszczególnych grupach pacjentów)
sGHD pGHD ISS
H SDS –2.50±0.89a, b –2.10±0.62a –2.13±0.61b
TH SDS –0.70±0.81 –0.62±0.72 –0.76±0.76
PAH SDS –1.70±0.91c, d –1.00±1.05c, e –1.26±0.96d, e
IGF-I SDS –0.49±1.27f, g 0.01±1.11f 0.27±1.39g
significant differences: a–e — p < 0.05, f–g — p < 0.001
Figure 1. Comparison of H SDS at diagnosis in particular groups
of patients
Rycina 1. Porównanie H SDS w momencie rozpoznania w po-
szczególnych grupach pacjentów
Figure 2. Comparison of PAH SDS in particular groups of
patients
Rycina 2. Porównanie PAH SDS w poszczególnych grupach
pacjentów
Figure 3. Comparison of IGF-I SDS in particular groups of
patients
Rycina 3. Porównanie IGF-I SDS w poszczególnych grupach
pacjentów
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normally growing children maximal GH secretion
fulfilled the criteria of GHD in many cases, being below
10 ng/mL [24] or even below 7 ng/mL in about 50% chil-
dren of normal height and below 5 ng/mL in 30% of
them [25].
Of particular interest is the study of Nwosu et al. [26],
who assumed that the characteristics of patients with
pGHD should be intermediate between those with
sGHD and ISS. However, it turned out that the patients
with pGHD constituted a group that was similar to those
with ISS in all the features analysed, except in the re-
sults of GH stimulation tests, the basis on which the
groups were separated. The results obtained in our stu-
dy are very similar. Thus there is no evidence for the
establishment of a border between normal and subnormal
results of GH stimulation tests at the level of 10 ng/mL.
In explanation of the above-mentioned findings, acco-
unt should be taken of the poor reproducibility of GH
stimulation tests [2, 5, 6] as well as of the possibility of
obtaining a falsely decreased GH peak in both stimula-
tion tests performed in a patient who is not GH-defi-
cient [4, 27].
It is worth recalling that the most important pro-
blem in diagnosing children with short stature is not
assessment of GH secretion but, first of all, identifica-
tion of those patients who may benefit from GH thera-
py. In recent years the results of numerous studies have
indicated that GH application may improve growth and
increase the final height of children with ISS (defined
as a normal GH response to pharmacological stimula-
tion). For instance, in 2003 Frindik et al. [28] stated that
there was no difference in near final height between
children with idiopathic GHD and those with ISS tre-
ated with GH. In the same year a summary of Austra-
lian experience was published [29], strongly confirming
the significance of auxology-based criteria in qualify-
ing children for GH therapy. In 2004 a randomised do-
uble-blinded, placebo-controlled study was published,
which confirmed the beneficial effect of GH therapy on
near adult height in patients with ISS [30]. Next, Miller
and Zimmerman [31] reported that GH treatment of
children with ISS should not be withheld because of
the inadequacy of current diagnostic tests. In the same
year, Badaru and Wilson [8] stated that there was no
longer evidence to use GH stimulation tests to diagno-
se childhood GHD and that alternative diagnostic tools
should be applied, including auxological, biochemical,
neuroradiological and genetic examinations. In 2005
Kemp et al. [32], in a relatively long-term cohort study,
demonstrated the efficacy of GH therapy, resulting in
a significant increase in H SDS in patients with ISS. In
the same year Park and Cohen [33] reported that many
patients with ISS had responded to GH therapy. The
authors proposed measurements of IGF-I secretion in
monitoring GH treatment in ISS patients to distinguish
those in whom the therapy might be effective from
others who suffered from partial or complete GH in-
sensitivity. This year Ranke et al. [34] have published
the results of the KIGS (Pfizer International Growth
Database) study, confirming the effectiveness of GH
therapy in children with ISS. In their analysis a good
first-year response to GH therapy was demonstrated
as a factor indicating the benefits of long-term treatment.
As many doubts concerning GH stimulation tests in
the diagnosis of GHD still exist and as the effectiveness
of GH therapy in patients with ISS seems to be well
documented, the qualification of short children for GH
therapy should not be based solely on the results of GH
stimulation tests. It should be stressed that there is no
evidence to disqualify a child from GH therapy on the
ground of GH peak in stimulation tests that was pre-
viously established as normal. It seems that other tools,
including more detailed auxological examinations and
prediction of final height, assessment of spontaneous
GH secretion, IGF-I measurements and monitoring of
HV before and during GH administration, should be
widely introduced into diagnostic protocols.
Finally, one more problem should be indicated, at
least briefly. In diagnosing the causes of short stature
other factors unrelated to decreased GH secretion, sho-
uld also be taken into account, especially if GH secre-
tion seems normal. In our study, the patients with ISS
had, as a group, a worse PAH than those with pGHD,
even despite a slightly better IGF-I secretion. The po-
ssibility of decreased GH sensitivity in some cases sho-
uld be considered in order to identify those patients who
should not be subjected to GH therapy.
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